[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-362391-105":59,"doc-detail-362391-en":134},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":127,"head_meta":129,"extra_data":131,"updated_unix":133},105,"en","pharmacological-wee1-inhibition-as-a-strategy-to-overcome-cisplatin-resistance-in-non-seminoma-testicular-cancer-insights-from-preclinical-models","Pharmacological WEE1 inhibition as a strategy to overcome cisplatin resistance in non-seminoma testicular cancer - insights from preclinical models","","Testicular germ cell tumors include a clinically aggressive non-seminoma subtype where cisplatin (CP) resistance limits durable responses. This preclinical study evaluates whether WEE1 inhibition using adavosertib can overcome CP resistance. Using non-seminoma cell lines NCCIT and NT2/D1 and their CP-resistant subclones, effects of adavosertib alone or combined with CP were measured for viability, cell-cycle progression, apoptosis, and DNA damage markers. Adavosertib reduced viability in 2D/3D models, disrupted S-phase and mitosis control, increased DNA damage and apoptotic signals, and enhanced CP efficacy even in resistant lines.",{"@graph":69,"@context":126},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/pharmacological-wee1-inhibition-as-a-strategy-to-overcome-cisplatin-resistance-in-non-seminoma-testicular-cancer-insights-from-preclinical-models/362391/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/pharmacological-wee1-inhibition-as-a-strategy-to-overcome-cisplatin-resistance-in-non-seminoma-testicular-cancer-insights-from-preclinical-models/362391.png","ImageObject",300,407,{"name":92,"@type":93},"Rhys","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-18","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118,122],{"name":109,"@type":110,"acceptedAnswer":111},"Why target WEE1 in non-seminoma testicular cancer?","Question",{"text":112,"@type":113},"WEE1 is a key cell-cycle regulator, and cisplatin resistance is linked to DNA damage response pathway changes. Inhibiting WEE1 is used to disrupt cell-cycle control and sensitize cells to DNA-damaging chemotherapy.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What cell models were used to test adavosertib and cisplatin?",{"text":117,"@type":113},"The study used two non-seminoma cell lines (NCCIT and NT2/D1) and their CP-resistant subclones (NCCIT-R and NT2/D1-R), evaluating drug effects across both 2D and 3D cultures.",{"name":119,"@type":110,"acceptedAnswer":120},"What mechanisms did adavosertib cause at the cellular level?",{"text":121,"@type":113},"Adavosertib reduced viability in a dose-dependent manner, altered cell-cycle distribution by increasing S-phase, and increased CDK1 activity and mitotic marker pH3, indicating disrupted cell-cycle control. This resulted in replication stress, early mitosis with DNA damage, mitotic catastrophe, and higher apoptosis markers.",{"name":123,"@type":110,"acceptedAnswer":124},"Does combining adavosertib with cisplatin improve efficacy in resistant models?",{"text":125,"@type":113},"Yes. Combination treatments enhanced cisplatin effectiveness across all tested models, including CP-resistant lines, supporting WEE1 inhibition plus standard chemotherapy as a promising strategy.","https://schema.org",{"og:url":83,"og:type":128,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":130,"canonical":83},"index,follow",{"doc_id":132,"site_id":62},362391,1790295659,{"code":4,"msg":5,"data":135},{"doc_id":132,"user_id":136,"nickname":92,"user_avatar":137,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":138,"file_id":139,"file_url":140,"file_type":141,"file_size":142,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":143,"language":144,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":145,"faqs":146,"seo_title":147,"seo_description":67,"update_tm":148,"read_time":149,"preview_page_count":19,"preview_urls":150},687207024643,"https://ap-avatar.wpscdn.com/davatar_3d24733baf745e90a7e4bdd5f77d97b2","[www. nature.com/scientificreports](www. nature.com/scientificreports)  \nOPEN  \nPharmacological WEE1 inhibition as a strategy to overcome cisplatin resistance in non-seminoma testicular cancer: insights from preclinical models  \nMariangela Tamburello1,7, Caterina Boldini1,7, Andrea Abate1􀀍, Valentina Salvi2, Francesca Valcamonico3, Marta Laganà3, Deborah Cosentini3, Nazareno R. Suardi4, Giuseppe Mirabella4, Barbara Altieri5,6 & Sandra Sigala1  \nTesticular germ cell tumors are the most common solid malignancy in young adult males with  \nnon-seminomatous representing a clinically aggressive subtype. Although cisplatin (CP)-based chemotherapy is highly effective, a subset of patients develop resistance. This study explored a potential new treatment by targeting WEE1, a key cell-cycle regulator, using the drug adavosertib in non-seminoma cell models, aiming to overcome CP resistance. Two non-seminoma cell lines, NCCIT and NT2/D1, and their CP-resistant subclones (NCCIT-R and NT2/D1-R) were used. The effects of adavosertib and CP, alone or in combination, on cell viability, cell-cycle progression, apoptosis, and DNA damage markers was assessed. WEE1 was expressed in non-seminoma cell models. Adavosertib reduced cell viability in a dose-dependent manner across all cell models in both 2D and 3D cultures. IC50 values were in low micromolar range (NCCIT: 0.550 µM; NCCIT-R: 0.630 µM; NT2/D1: 0.415 µM; NT2/  \nD1-R: 0.630 µM). Adavosertib altered cell-cycle distribution, increasing S-phase population. Western blot analysis revealed that inhibiting WEE1 increases CDK1 activity and mitotic marker pH3, indicating disrupted cell cycle control. This leads to replication stress and forces cells with DNA damage into early mitosis, causing mitotic catastrophe. The treatment also triggered higher levels of DNA damage and cell death, as shown by increased caspase activity and apoptosis markers (cleaved-PARP and cleavedCaspase 3). In combination treatments, adavosertib enhanced CP efficacy across all models, including resistant lines. Overall, our results provide compelling preclinical evidence supporting the combination of WEE1 inhibition with standard chemotherapy as a promising strategy to overcome CP-resistance in non-seminoma testicular cancer.  \nKeywords Testicular cancer, Cisplatin resistance, WEE1 inhibitors, Adavosertib, Debio 0123, Combined treatment  \nTesticular cancer (TC) is a heterogeneous disease, with the majority (90–95%) arising from germ cells (GCTs), followed by sex cord-gonadal stromal tumours and secondary tumours1. Testicular germ cell tumours (TGCTs) account for 1–1.5% of all male cancers and are the most common malignancy in males aged 15–40 years2, with incidence rates highest in Scandinavian and lowest in African and Asian populations3. According to the World Health Organization, TGCTs are classified into seminomas and non-seminomas, which differ markedly in treatment approaches and therapeutic response4. Seminomas are relatively homogeneous tumours derived  \n1Section of Pharmacology, Department of Molecular and Translational Medicine, University of Brescia, Brescia, Italy. 2Department of Molecular and Translational Medicine, University of Brescia, Brescia, Italy. 3Oncology Unit, Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, University of Brescia at ASST Spedali Civili di Brescia, Brescia, Italy. 4Urology Unit, Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, University of Brescia at ASST Spedali Civili di Brescia, Brescia, Italy.  \n5Division of Endocrinology and Diabetes, Department of Internal Medicine I, University Hospital, University of Würzburg, Würzburg, Germany. 6Bavarian Cancer Research Center (BZKF), Würzburg, Germany. 7Mariangela Tamburello and Caterina Boldini equally to this work and are co-primary authors. 􀀍 email: [andrea.abate@unibs.it](andrea.abate@unibs.it)  \n[www. nature.com/scientificreports/](www. nature.com/scientific","cbCaidvz6ug1PD8q","https://ap.wps.com/l/cbCaidvz6ug1PD8q","pdf",5304563,13,"English","# Introduction\n# Rationale for targeting WEE1\n## CP resistance in non-seminoma\n# Experimental approach\n## Cell models and CP-resistant subclones\n## Treatment conditions and assays\n# Findings\n## WEE1 expression and adavosertib cytotoxicity\n## Cell-cycle disruption and replication stress\n## Apoptosis, DNA damage, and caspase activation\n# Combination strategy with CP\n# Conclusion","[{\"question\":\"Why target WEE1 in non-seminoma testicular cancer?\",\"answer\":\"WEE1 is a key cell-cycle regulator, and cisplatin resistance is linked to DNA damage response pathway changes. Inhibiting WEE1 is used to disrupt cell-cycle control and sensitize cells to DNA-damaging chemotherapy.\"},{\"question\":\"What cell models were used to test adavosertib and cisplatin?\",\"answer\":\"The study used two non-seminoma cell lines (NCCIT and NT2/D1) and their CP-resistant subclones (NCCIT-R and NT2/D1-R), evaluating drug effects across both 2D and 3D cultures.\"},{\"question\":\"What mechanisms did adavosertib cause at the cellular level?\",\"answer\":\"Adavosertib reduced viability in a dose-dependent manner, altered cell-cycle distribution by increasing S-phase, and increased CDK1 activity and mitotic marker pH3, indicating disrupted cell-cycle control. This resulted in replication stress, early mitosis with DNA damage, mitotic catastrophe, and higher apoptosis markers.\"},{\"question\":\"Does combining adavosertib with cisplatin improve efficacy in resistant models?\",\"answer\":\"Yes. Combination treatments enhanced cisplatin effectiveness across all tested models, including CP-resistant lines, supporting WEE1 inhibition plus standard chemotherapy as a promising strategy.\"}]","Pharmacological WEE1 inhibition as a strategy to overcome cisplatin resistance in non-seminoma testicular cancer - insights from preclinical models | PDF",1790147508,33,[151,155,159,163],{"page_no":8,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ab8a6801ee316154c1c8df8eae5dd6c3.webp",983,1291,{"page_no":14,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/103941c336ca1e646cebb7c5990000cd.webp",982,1290,{"page_no":81,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e62553a9c80d31fed99c40519516a59b.webp",981,1289,{"page_no":19,"url":164,"width":165,"height":166},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8c1b5a277819389b1852a0b503115035.webp",980,1287]